Medroxyprogesterone reduces the incidence and severity of hot flashes in men who receive gonadotropin releasing hormone agonists

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1505, 2005-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gonadotropin releasing hormone agonists/medroxyprogesterone/tamoxifen: Acute promyelocytic leukaemia?: case report

By  

Reactions Weekly, Vol. 1, Iss. 1222, 2008-01 ,pp. : 18-19

Adis International

Access to resources Recommend Favorite

Emerging gonadotropin-releasing hormone agonists

By Beyer Daniel Alexander   Amari Feriel   Thill Marc   Schultze-Mosgau Askan   Al-Hasani Safaa   Diedrich Klaus   Griesinger Georg  

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 2, 2011-06 ,pp. : 323-340

Informa Healthcare

Access to resources Recommend Favorite

Gonadotropin-releasing hormone agonists in breast cancer

By  

Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Gonadotropin-Releasing Hormone Agonists and the Risks of Type 2 Diabetes and Cardiovascular Disease in Men with Prostate Cancer

By Saylor Philip J.  

Drugs, Vol. 71, Iss. 3, 2011-02 ,pp. : 255-261

Adis International

Access to resources Recommend Favorite

New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists

By Schultze-Mosgau Askan   Griesinger Georg   Altgassen Christopher   von Otte Soeren   Hornung Daniela   Diedrich Klaus  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 9, 2005-09 ,pp. : 1085-1097

Informa Healthcare

Access to resources Recommend Favorite